Overview
- The FDA convened a two-day advisory meeting on July 23–24, 2026 to evaluate seven peptides popularized on social media, including BPC-157 and TB-500.
- In a pre-meeting technical report, career FDA scientists recommended not authorizing any of the seven peptides for compounding because human clinical data are sparse.
- The agency has warned of risks from these products such as contamination of injectables, allergic reactions, and poor quality control tied to unclear composition.
- At least seven advisory-panel members disclosed financial ties to the peptide industry, prompting the FDA to add non-commercial academic experts and stirring public scrutiny.
- The agency received more than 1,900 public comments and observers expect the FDA to issue a cautious, short-term policy that reassures compounding pharmacies without formally approving the peptides, while any permanent change would require a much longer rulemaking process.